Details of the Drug

General Information of Drug (ID: DMXYM1H)

Drug Name
Visilizumab
Synonyms Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
UNII
H18SKU3289
DrugBank ID
DB12053
TTD ID
D0OH8W

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Regulatory protein unspecific (RGP) TTBMAOZ NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00502294) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis. U.S. National Institutes of Health.
2 Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.